Expression of activated Notch1 and Hey1 in papillary thyroid carcinoma

Jung, Chang Won; Kong, Jun Suk; Seol, Hyesil; Park, Sunhoo; Koh, Jae Soo; Lee, Seung Sook; Kim, Min Joo; Choi, Ik Joon; Myung, Jae Kyung

doi:10.1111/his.13065

Cited by 18 publications

(14 citation statements)

References 22 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been confirmed in some literature that Notch1 expression is increased in PTC and can promote downstream Jagged1 expression by activating the Notch signaling pathway, affecting the apoptosis, proliferation and invasion of PTC cells (29). In the present study, the Notch signaling pathway inhibitor DAPT was used to treat thyroid carcinoma cells TPC-1.…”

Section: Discussionsupporting

confidence: 65%

Effect of miR‑449a‑mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells

Hou¹,

Feng

Yang

2019

Oncol Rep

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 65%

Effect of miR‑449a‑mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells

Hou¹,

Feng

Yang

2019

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Jung et al examined the relationship between clinicopathological factors and HEY1 expression in 109 cases of papillary thyroid carcinoma. HEY1 immunoreactivity was positively correlated with lymph node metastasis, recurrence and metastasis [34]. However, Ménard M et al showed that HEY1 inhibited tumor progression by regulating tropomyosin receptor kinase C (TrkC) activity in neuroblastoma [35].…”

Section: Discussionmentioning

confidence: 99%

The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells

et al. 2020

View full text Add to dashboard Cite

Our previous study demonstrated a close relationship between the NOTCH signaling pathway and salivary adenoid cystic carcinoma (SACC). Its receptor gene, NOTCH1, and its downstream gene, HES1, contribute to the proliferation, invasion and metastasis of SACC. Accumulating evidence supports HEY1 as another effector of the signaling pathway. The purpose of this study was to explore the effects of the NOTCH1-HEY1 pathway on the proliferation, invasion and metastasis of SACC cells. Our results verified that HEY1 is a specific molecular target of the NOTCH signaling pathway in SACC cells and that its expression in carcinoma is much higher than that in paracarcinoma tissues. The expression of NOTCH1 and HEY1 are positively correlated in the salivary adenoid cystic carcinoma tissues. NOTCH1 is significantly related to the activation of HEY1 in SACC, and that HEY1 reciprocally regulates NOTCH1 expression in SACC. HEY1 promotes cell proliferation and spheroid formation and inhibits cell apoptosis in vitro. In addition, HEY1 enhances the tumorigenicity of SACC in vivo. Furthermore, HEY1 increases cell invasion and metastasis by driving the expression of epithelial-mesenchymal transition (EMT)-related genes and MMPs. The results of this study indicate that the NOTCH1-HEY1 pathway is specifically upregulated in SACC and promotes cell proliferation, self-renewal, invasion, metastasis and the expression of EMT-related genes and MMPs. Our findings suggest that a NOTCH1-HEY1 pathway inhibitor might therefore have potential therapeutic applications in treating SACC patients by inhibiting cancer cell growth and metastasis.

show abstract

“…Although differentiated PTC carries a favorable prognosis, it causes a postoperative recurrence rate as high as 30% during long-term follow-up [ 3 ]. A few biomarkers have been identified for the diagnosis of PTC, including EHD2 [ 4 ], Notch signaling [ 5 ], HER-2/neu [ 6 ], and CXCL12 [ 7 ], without clear evidence of their efficacy for clinical use. Therefore, the identification and validation of reliable biomarkers for diagnostic and prognostic prediction of PTC is urgently needed in clinical work.…”

Section: Introductionmentioning

confidence: 99%

Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma

Shi

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

ObjectiveThe prevalence of papillary thyroid carcinoma (PTC) is rising rapidly. However, there are no reliable serum biomarkers for PTC. This study aimed to investigate the validity of preoperative serum matrix metalloproteinase-2 (MMP-2) as a biomarker for predicting prognosis of PTC after total or partial thyroidectomy.MethodsMale patients with PTC or a benign thyroid nodule (BTN) and healthy controls (HCs) were retrospectively included. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of preoperative serum MMP-2 in diagnosing PTC, predicting lymph node metastasis (LNM), and predicting structurally persistent/recurrent disease (SPRD). Multivariate logistic regression and Cox regression were applied to identify independent risk factors for SPRD.ResultsThe preoperative serum MMP-2 concentration in the PTC group was higher than those in BTN and HC groups. The concentration of postoperative serum MMP-2 decreased in comparison with pre-operation. ROC curves showed that serum MMP-2 could differentially diagnose PTC from BTN at the cutoff value of 86.30 ng/ml with an area under the curve (AUC) of 0.905 and could predict central LNM (CLNM) at the cutoff value of 101.55 ng/ml with an AUC of 0.711. Serum MMP-2 ≥101.55 ng/ml, age ≥45 years, and advanced TNM stage were independent risk factors for CLNM. Patients with SPRD had a higher median MMP-2 level (149.22 ng/ml) than patients without SPRD (104.55 ng/ml). Serum MMP-2 at the cutoff value of 144.04 ng/ml could predict SPRD in PTC patients with an AUC of 0.803. Advanced TNM stage and serum MMP-2 ≥144.04 ng/ml were independent risk factors for SPRD. Patients with serum MMP-2 ≥144.04 ng/ml had a worse clinical outcome than those with MMP-2 <144.04 ng/ml.ConclusionPreoperative serum MMP-2 may serve as a biomarker for diagnosing PTC and a predictive indicator for LNM and SPRD in male patients with PTC.

show abstract

Expression of activated Notch1 and Hey1 in papillary thyroid carcinoma

Abstract: Thus, we found that activation of Notch signalling was correlated significantly with clinicopathological parameters. Therefore, Notch signalling could be a useful prognostic marker in patients with PTC.

Cited by 18 publications

References 22 publications

Effect of miR‑449a‑mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells

Effect of miR‑449a‑mediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells

The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells

Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma

Contact Info

Product

Resources

About